Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[02/07/2018]

UCB : UCB Media Room: Neupro Approval in China

UCB announces approval of NEUPRO® in China to treat Parkinson’s DiseaseNEUPRO now approved in China for the treatment of the signs and symptoms of earlystage idiopathic Parkinson’s Disease as monotherapy i.e. without levodopa or in combination with levodopaNEUPRO approval in China reinforces UCB’s ongoing commitment to supporting patient value across China and to offering Chinese patients... See more
 
UCB [BE0003739530/UCB]   
[28/06/2018]

UCB : UCB Media Room: IFPA 2018 Data Release

New UCB Research Showcases Value of CIMZIA® certolizumab pegol in Psoriasis and Highlights Unique Experiences and Real World Evidence for Key Patient PopulationsCIMZIA, the only Fcfree, PEGylated antiTNF, recently received marketing authorization from the European Commission for the treatment of adults with moderate to severe plaque psoriasisBrussels, Belgium – 28 June 2018 – UCB, a global... See more
 
UCB [BE0003739530/UCB]   
[15/06/2018]

UCB : UCB Media Room: EULAR 2018 AIM Survey

New Study Presented at the Annual European Congress of Rheumatology EULAR 2018 Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy JourneySurvey reveals that women of childbearing age with chronic rheumatic diseases experience unique challenges, and suggests many experience a lack of guidance and consistent information regarding family planning and treatment during... See more
 
UCB [BE0003739530/UCB]   
[13/06/2018]

UCB : Media Room: UCB Ventures makes its first direct investment

UCB Ventures makes its first direct investmentSeries A Financing for StrideBio, Inc. Brussels, Belgium, 13 June 2018. – Today, UCB Ventures announces its first direct investment in the oversubscribed $15.7 million Series A Financing Round for StrideBio, Inc., a USbased biotechnology company developing novel adenoassociated viral AAV vectors for in vivo gene therapies of rare diseases. The... See more
 
UCB [BE0003739530/UCB]   
[07/06/2018]

UCB : UCB Media Room: EULAR 2018 Data Highlights Release

New UCB Data Presented at the Annual European Congress of Rheumatology EULAR 2018 Serves Key Patient Populations Including Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic Inflammatory DiseasesLatebreaking oral presentation on bimekizumab demonstrates significant potential for treating ankylosing spondylitis ASOral presentation on CIMZIA® certolizumab pegol pregnancy outcomes... See more